A small number of case reports of steatorrhoea after allogenic BMT have been published, but the incidence and natural history of this complication have not been defined. We reviewed the incidence of steatorrhoea in 184 consecutive allograft recipients surviving at least 100 days. Steatorrhoea was documented in five patients, a median of 5.5 months (range 4-14) post-transplant. All patients had recent or concomitant acute gut or liver graft versus host disease (GVHD). The probability of developing steatorrhoea by 2 years post-transplant was 3.3% (95% confidence interval (CI) +/- 2.9% in the group overall, rising to 4.8% (CI +/- 4.2%) in patients with acute and/or extensive chronic GVHD. All patients responded clinically to pancreatic enzyme supplements. While these observations are consistent with previously reported autopsy data suggesting that GVHD of the exocrine pancreas is likely to be predominant underlying pathological process, in two patients concomitant small bowel or hepatic dysfunction may have contributed to the severity of steatorrhoea. Enzyme supplements were subsequently ceased in three patients without return of steatorrhoea, suggesting that the process is usually reversible. Our data demonstrate that steatorrhoea is not infrequent complication in the 2 years postallograft, particularly in patients with GVHD.

中文翻译：

---

骨髓移植后脂肪泻的发生，发病机制和自然病史。

少数同种异体BMT术后脂肪性痢疾的病例报道已经发表，但是这种并发症的发生率和自然病程尚未明确。我们复查了至少存活100天的184个连续同种异体移植患者的脂肪性肝炎的发生率。已有5例患者记录有Steerrhoea，移植后中位数为5.5个月（范围4-14）。所有患者均患有近期或伴随的急性肠道或肝移植物抗宿主病（GVHD）。总体而言，该组患者在移植后2年内发展为硬脑膜炎的可能性为3.3％（95％置信区间（CI）+/- 2.9％），在急性和/或急性期患者中上升到4.8％（CI +/- 4.2％）或广泛的慢性GVHD。所有患者在临床上均对胰腺酶补充剂有反应。虽然这些观察结果与以前报道的尸检数据一致，提示外分泌胰腺的GVHD可能是主要的潜在病理过程，但在两名患者中，伴有小肠或肝功能障碍的可能是硬脑膜炎的严重程度。随后在三名患者中停止了酶补充剂治疗，而没有返回硬脑膜炎，这表明该过程通常是可逆的。我们的数据表明，在同种异体移植后的2年中，尤其是在GVHD患者中，脂溢性皮炎并非罕见。随后在三名患者中停止了酶补充剂治疗，而没有返回硬脑膜炎，这表明该过程通常是可逆的。我们的数据表明，在同种异体移植后的2年内，尤其是在GVHD患者中，脂溢性皮炎并非罕见。随后在三名患者中停止了酶补充剂治疗，而没有返回硬脑膜炎，这表明该过程通常是可逆的。我们的数据表明，在同种异体移植后的2年中，尤其是在GVHD患者中，脂溢性皮炎并非罕见。